A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Trial Profile

A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational
  • Acronyms OPT Extend
  • Sponsors Pfizer
  • Most Recent Events

    • 31 May 2017 This trial has been completed in Germany (End date:2016-06-22) as per European Clinical Trials Database record.
    • 09 Mar 2017 This trial was completed in Greece according to the European Clinical Trials Database record.
    • 03 Sep 2016 This trial was completed in Austria (End Date: 22 Jun 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top